Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -40.18% is 68% above its 4-year average of -126.49%, near the high end of its 4-year range (-489.13%–5.99%).
10.15% above its 12-month average of -44.72%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -12.33%.
RETURN ON ASSETS (ROA)
-40.18%
RETURN ON ASSETS (ROA) AVG TTM
-44.72%
RETURN ON ASSETS (ROA) AVG 3Y
-159.61%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+10.15%
CURRENT VS 3Y AVG
+74.83%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-24.63%
vs the sector median at left
Zura Bio Limited
Market Cap
$376.19M
Return on Assets (ROA)
-40.18%
TTM Avg
-44.72%
3Y Avg
-159.61%
5Y Avg
N/A
Market Cap
$376.01M
Return on Assets (ROA)
-24.06%
TTM Avg
-44.34%
3Y Avg
-68.40%
5Y Avg
-50.78%
Market Cap
$374.50M
Return on Assets (ROA)
-69.44%
TTM Avg
-48.37%
3Y Avg
-55.05%
5Y Avg
-50.20%
Market Cap
$380.37M
Return on Assets (ROA)
-7.07%
TTM Avg
-12.47%
3Y Avg
-11.40%
5Y Avg
-8.86%
Market Cap
$369.50M
Return on Assets (ROA)
-41.58%
TTM Avg
-23.89%
3Y Avg
-13.16%
5Y Avg
-19.94%
Market Cap
$385.15M
Return on Assets (ROA)
-50.81%
TTM Avg
-45.77%
3Y Avg
-42.77%
5Y Avg
-29.22%
Market Cap
$361.64M
Return on Assets (ROA)
-115.75%
TTM Avg
-127.38%
3Y Avg
-59.19%
5Y Avg
-98.90%
Market Cap
$359.53M
Return on Assets (ROA)
-4.29%
TTM Avg
-7.44%
3Y Avg
-40.66%
5Y Avg
-49.61%
Market Cap
$396.93M
Return on Assets (ROA)
-23.05%
TTM Avg
-30.00%
3Y Avg
-27.77%
5Y Avg
-27.77%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zura Bio Limited (ZURA) | $376.19M | -40.18% | -44.72% | -159.61% | N/A |
| Canopy Growth Corporation (CGC)vs › | $376.01M | -24.06% | -44.34% | -68.40% | -50.78% |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $374.50M | -69.44% | -48.37% | -55.05% | -50.20% |
| Orthofix Medical Inc. (OFIX)vs › | $380.37M | -7.07% | -12.47% | -11.40% | -8.86% |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $369.50M | -41.58% | -23.89% | -13.16% | -19.94% |
| REGENXBIO Inc. (RGNX)vs › | $385.15M | -50.81% | -45.77% | -42.77% | -29.22% |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | -115.75% | -127.38% | -59.19% | -98.90% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | -4.29% | -7.44% | -40.66% | -49.61% |
| Shoulder Innovations, Inc. (SI)vs › | $396.93M | -23.05% | -30.00% | -27.77% | -27.77% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | -24.64% | -45.98% | -40.55% | -44.33% |
ROA
-40.2%
ROE
-43.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -60.25% |
| 2024-12-31 | -29.19% |
| 2023-12-31 | -59.86% |
| 2022-12-31 | -489.13% |
| 2022-03-31 | 5.99% |
